Semaglutida ha demostrado en estudios como SUSTAIN y STEP reducciones consistentes en triglicridos (aproximadamente 12-17%) y colesterol LDL (3-6%), con variaciones segn dosis y poblacin
however, in the past week, President Trump announced deals with makers of GLP-1 drugs to offer their drugs at cheaper prices directly to consumers
The goal isnt rapid or dramatic weight loss its the everyday health benefits that GLP-1 therapy supports: reduced food noise, better digestion, lower inflammation, and improved metabolic health
C.YanA.ElhadadS.WeitmanE
For those seeking targeted fat loss without systemic hormonal changes, AOD-9604 s selectivity creates a safety advantage
and in July 2024, the FDA approved Kisunla (donanemab) for early symptomatic Alzheimers, based on evidence of reduced clinical decline and a limitedduration regimen tied to amyloid plaque removal